Table 1.
Patient Flow and Inclusion and Exclusion Criteria
| Patient Numbers | Inclusion/Exclusion Criteria | Number Excluded |
|---|---|---|
| 3,460,270 | All patients in the OPCRD | NA |
| BDP/FF 30,933 FP/SAL 34,842 BUD/FF 97,997 |
Inclusion: initiated on licensed ICS/LABA combination inhaler |
3,296,498 |
| BDP/FF 6,744 FP/SAL 22,854 BUD/FF 30,819 |
Inclusion: COPD diagnosis, FEV1/FVC<0.7 |
BDP/FF 24,159 FP/SAL 11,988 BUD/FF 67,178 |
| BDP/FF 3,586 FP/SAL 15,678 BUD/FF 22,275 |
Inclusion: 1 year of data prior to and after initiation of licensed ICS/LABA combination inhaler |
BDP/FF 3,188 FP/SAL 7,176 BUD/FF 8,544 |
| BDP/FF 3,573 FP/SAL 15,637 BUD/FF 22,150 |
Inclusion: aged 35 years or older |
BDP/FF 13 FP/SAL 41 BUD/FF 125 |
| BDP/FF 2,999 FP/SAL 13,645 BUD/FF 18,629 |
Inclusion: at least two prescriptions of licensed ICS/LABA combination inhaler in the outcome period (including index date) |
BDP/FF 574 FP/SAL 1,992 BUD/FF 3,521 |
| BDP/FF 2,405 FP/SAL 11,339 BUD/FF 15,805 |
Inclusion: no change of ICS/LABA combination inhaler in outcome period |
BDP/FF 594 FP/SAL 2,306 BUD/FF 2,824 |
| BDP/FF 1,550 FP/SAL 7,929 BUD/FF 8,577 |
Inclusion: At least one prescription of LABA and/or LAMA and/or unlicensed ICS/LABA combination inhaler prior to index date |
BDP/FF 855 FP/SAL 3,410 BUD/FF 7,228 |
| BDP/FF 1,065 FP/SAL 5,640 BUD/FF 5,969 |
Inclusion: At least one exacerbation in the prior 18 months |
BDP/FF 485 FP/SAL 2,289 BUD/FF 2,608 |
| BDP/FF 573 FP/SAL 3,628 BUD/FF 3,669 |
Inclusion: FEV1 <55% predicted recorded ever |
BDP/FF 492 FP/SAL 2,012 BUD/FF 2,300 |
| BDP/FF 549 FP/SAL 3,416 BUD/FF 3,419 |
Exclusion: documented nonsmoker or no documented smoking status | BDP/FF 24 FP/SAL 212 BUD/FF 250 |
| BDP/FF 549 FP/SAL 3,374 BUD/FF 3,001 |
Exclusion: duplicate patientsa | BDP/FF 0 FP/SAL 42 BUD/FF 418 |
Notes: aPatients prescribed more than one ICS/LABA combination inhalers were assigned to the BDP/FF group.